Abstract In this study, we demonstrate, for the first time, the localization of insulin-like growth factor I (IGF-I) in de novo and restenotic human coronary atherectomy plaques by using immunocytochemical techniques. Smooth derived growth factor (PDGF)-stimulated cultures were minimally affected by the addition of octreotide but were significantly inhibited by angiopeptin. All three growth factors stimulated SMC migration in a dose-dependent manner. The somatostatin analogues tested had no effect on growth factorstimulated SMC migration. Our data suggest that by reducing SMC proliferation, somatostatin analogues may have clinical usefulness in reducing the high incidence of restenosis observed after percutaneous transluminal coronary artery interventions. (Circulation. 1994;89:1511-1517 suggesting that expression for 8 
T nhe major limitation of percutaneous transluminal coronary artery interventions remains the high restenosis rate, occurring in as many as 57% of patients.1 Despite advances in catheter-based technology such as directional, rotational, or excimer laser atherectomy, the recurrence rate has not been reduced.23 A major breakthrough in understanding the pathophysiological processes that determine restenosis was recognition that a critical step in the chain of events is injury-induced activation of vascular smooth muscle cells (SMCs), resulting in cell proliferation and migration into the subintima.4-6 These same cellular and molecular mechanisms may be responsible for the excessive SMC proliferation observed in transplant arteriopathy. 7 Growth factors such as platelet-derived growth factor (PDGF), basic fibroblast growth factor (b-FGF), and insulin-like growth factor (IGF-I) have been implicated in the regulation of SMC proliferation and migration because all are potent SMC mitogens in vitro and induce SMC chemotaxis.8-10 PDGF and b-FGF have been localized in human coronary atheroma by immunocytochemical techniques. Nikol and coworkers1" recently demonstrated expression of transforming growth factor-f,l 8) in human coronary primary atherosclerotic or restenotic lesions by in situ hybridization, derived growth factor (PDGF)-stimulated cultures were minimally affected by the addition of octreotide but were significantly inhibited by angiopeptin. All three growth factors stimulated SMC migration in a dose-dependent manner. The somatostatin analogues tested had no effect on growth factorstimulated SMC migration. Our data suggest that by reducing SMC proliferation, somatostatin analogues may have clinical usefulness in reducing the high incidence of restenosis observed after percutaneous transluminal coronary artery interventions. (Circulation. 1994; 89:1511 -1517 suggesting that expression for TGF-,8 mRNA was significantly higher in restenotic compared with de novo lesions. These (TBS containing 0.1 mol/L NaCl, 1% BSA, 1% CWFG, and 1% NDM) followed by incubation for 1 hour at room temperature in goat anti-rabbit IgG secondary antibodies labeled with either 10 nm or 15 nm colloidal gold. Grids were washed 3 x 5 minutes in TBS followed by 3 x 5-minute washes in deionized water. Grids were examined and photographed in the electron microscope at 75 kV without poststaining. Controls for nonspecific labeling consisted of reaction with primary antibodies absorbed with IGF-I and reaction with secondary antibody without exposure to primary antibody.
Semiquantitation of the localization of IGF-I was done from representative electron micrographs at a final magnification of x25 000 by two observers blind to the identity of the type of plaque (de novo or restenotic). Colloidal gold particles were counted, and final counts were expressed per unit area.
Comparisons were made between synthetic SMCs2' (sSMCs) and contractile SMCs (cSMCs) within the same plaque.
Preparation of SMC Cultures
For preparation of human coronary SMCs, recipient hearts explanted at the time of orthotopic heart transplantation were obtained, and a segment of the coronary artery was dissected under sterile conditions. The endothelium was first removed by scraping with a rubber policeman, and then the tissue was cut into uniform 1-mm2 pieces using a Mclwain tissue chopper (Mickle Engineering, Surrey, UK). Each piece was placed in one well of a 2% gelatin-coated 96-well plate and covered with 100 ,L of Dulbecco's modified Eagle's medium (DMEM) containing 20% fetal bovine serum (FBS), 100 U/mL penicillin, 100 ,ug/mL streptomycin, and 0.25 ,ig/mL amphotericin B. Cultures were placed in a humidified incubator containing 5% CO2 at 37°C. Fresh media with 15% FBS were added by drops every 3 days until the tissue was just covered. By day 10, SMCs were radiating from the explant. Once cultures were established, tissue was removed, and cells within wells were allowed to reach confluence. Cells were expanded to 75-cm2 flasks for continued growth in media with 15% FBS. SMCs were verified by typical "hill-and-valley" morphology, as well as by immunocytochemical staining with a-actin antiserum:22 Cultures between passage levels 2 through 6 were used for these studies.
Proliferation and Cell Migration Studies
Single-cell suspensions of SMCs were plated in 24-well plates (5000 cells per well) in media with 2.5% FBS and allowed to adhere for 24 hours. After we washed the wells, media containing 2.5% FBS with the appropriate amount of growth factor alone or in combination with either octreotide (kind gift of Sandoz Pharmaceuticals) or angiopeptin (kind gift of Henri Beaufour Institute) were added to quadruplicate wells. Cells were counted on days 0, 2, 4, 6, 8, and 10. Day 0 represented 24 hours after initial seeding, ie, when growth factor and/or somatostatin analogue was added. Cells were enzymatically dissociated, and the entire well contents were counted using a model ZF Coulter Counter (Coulter Electronics, Hialeah, Fla).
For thymidine incorporation experiments, cells were plated as above; 10 nmol/L IGF-I or 10 nmol/L b-FGF, and increasing concentrations of octreotide were added to wells along with 5 ,uCi per well of [3H]thymidine. After an 18-hour incubation, wells were aspirated and washed three times. DNA was precipitated with trichloroacetic acid (TCA), solubilized with 0.3 N NaOH, and then counted in scintillation fluid.
Chemotaxis and chemokinesis assays were performed as previously described except that the assay duration was 12 hours and the optimal pore size for the porous polyvinyl-and pyrrolidone-free polycarbonate membrane (Nucleopore, Pleasanton, Calif) was 8 ,um.23 Each migration experiment was repeated a minimum of three times.
Statistical Analysis
The mean+SEM value for each set of studies was determined, and Student's t test was used to determine significance.
Results
IGF-I was localized in SMCs, macrophages, and foam cells, as well as in the extracellular matrix (ECM) of all plaques examined (n=10: 7 de novo and 3 restenotic).
Localization was most intense in sSMCs and often associated with endoplasmic reticulum-derived vesicles and cell processes (Fig 1A) . Specificity of the immunoreactivity for IGF-I was confirmed by the lack of labeling in an adjacent section of the same plaque reacted with IGF-I antibody absorbed with recombinant IGF-I (Fig 1B) . The intensity of IGF-I localization was markedly reduced in quiescent cSMCs compared with
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sSMCs in the same section of a given plaque (Fig 1C  and 1D ), but there was localization in the surrounding ECM. Mean (Fig 2a, top, open bars) . b-FGF-stimulated cells demonstrated a pronounced proliferative response at day 2, which plateaued at days 6 through 8 (Fig 2a, middle, open bars) . In a similar fashion, 10 nmol/L PDGF stimulated SMC proliferation, reaching maximal cell density on day 10 (Fig 2a,  bottom, open bars) .
SMC proliferation studies performed in the presence of IGF-I and octreotide are shown in the top panel of Fig 2a (filled bars) . On days 2, 4, and 6, octreotide induced a 15% to 20% inhibition of IGF-I-stimulated SMC proliferation, which achieved statistical significance (P<.01). Addition of octreotide to b-FGF-stimulated SMCs resulted in a 40% to 45% inhibition of cell proliferation on days 6 and 8 (Fig 2a, middle, filled bars) (P<.01). In contrast, PDGF-stimulated cell growth was not inhibited by octreotide (Fig 2a, bottom, filled bars) . Identical studies as performed with octreotide were performed using angiopeptin at a concentration of 30 nmol/L (Fig 2c) . This Both IGF-I and b-FGF induced human coronary artery SMC migration in a dose-dependent manner that began to plateau at approximately 125 ng/mL. The maximal response to IGF-I was 28-fold greater than in the BSA control, whereas the b-FGF response was 37-fold greater than the control response. Chemotactic activity was inhibited by the addition of either IGF-I or b-FGF antibodies. Using the concentrations of each growth factor shown to be effective in the cell proliferation assays, 25 to 100 ng, the effect of each somatostatin analogue on inhibition of SMC migration was assessed. The simultaneous addition of octreotide or angiopeptin and IGF-I or b-FGF to SMCs resulted in apparently fewer cells migrating compared with the wells containing growth factor alone; however, this did not achieve statistical significance (data not shown).
Discussion
We describe, for the first time, the ultrastructural localization of immunoreactive IGF-I in coronary atherectomy plaques. Intense localization of IGF-I occurred within the endoplasmic reticulum and cell processes of SMCs Exposure of SMCs to either PDGF, TGF-3, or b-FGF did not affect levels of either IGFBP-2 or IGFBP-4. Addition of IGFBP-4 to SMC cultures containing IGF-I had no effect on thymidine incorporation, whereas addition of IGFBP-4 to human fibroblasts with IGF-I resulted in near-complete inhibition of IGF-I-stimulated DNA synthesis.29 Taken together, these studies suggest that the factors that regulate IGFBPs vary and that this differential regulation may be an important mechanism by which SMC growth is controlled.
Our immunocytochemical studies and in vitro studies provide a firm basis for using somatostatin analogues for inhibition of SMC proliferation in accelerated atherogenesis. They also establish that somatostatin analogues could be more effective in inhibiting proliferation of rapidly proliferating SMCs rather than quiescent SMCs. Octreotide Concentration (nM) In this in vitro study, we demonstrate that IGF-I, b-FGF, and PDGF stimulate DNA synthesis and cell proliferation in human coronary SMCs. The stimulating effect of IGF-I and b-FGF is blocked by the somatostatin analogue octreotide, and this inhibition occurs at a low concentration (10 nmol/L) of octreotide. The effective dose is comparable to that used in studies of other cell types. Octreotide also exerted a dose-dependent inhibition of thymidine incorporation in human coronary SMCs. Angiopeptin demonstrates a similar effect but also blocks the effect of PDGF on SMC proliferation. The reason for this is not entirely clear but may be related to differences in each analogue's ability to stimulate PTPases or differences in the PTPases that modulate these three growth factors.
Although antibodies to IGF-I and b-FGF inhibited migration induced by these growth factors, the somatostatin analogues did not. This may be due to the requirement of this assay that a single-cell suspension of SMC be prepared, as only single cells can migrate through the pores of the filters used for these studies. This necessitates aggressive trypsinization. Somatostatin receptors may be particularly sensitive to trypsin treatment, and the 12-hour duration of the migration assay may not permit adequate recovery of the somatostatin receptor. The proliferation assays, in contrast, were performed over 10 days, giving ample time for the receptors to recover or regenerate. For these reasons, the modified Boyden chamber assay may not adequately assess the effect of somatostatin analogues on in vitro SMC migration.
All three growth factors considered in this study have been shown to be produced by SMCs.2731-33 The in vivo mitogenic potential of these growth factors for SMCs is complex. Local IGF-I in the pathogenesis of atherosclerosis. Local production of IGF-I by SMCs could facilitate SMC proliferation, thus contributing to the cellularity commonly seen in restenotic lesions.
Although extensive studies in the literature are available using aortic SMCs, studies using human coronary SMCs are extremely limited. Our results support the individual stimulatory effects of PDGF, IGF-I, and b-FGF on human coronary artery. Our data provide the basis to suggest the use of somatostatin analogues in the clinical setting to modify the high incidence of restenosis observed after coronary interventions by reducing SMC proliferation induced by IGF-I, b-FGF, and PDGF. 
M B Grant

